NUCM 215 Final (2026) – 350+ Questions on Radiopharmaceuticals, Thyroid Imaging, QC & Radionuclide Therapy

This NUCM 215 Final (2026) exam guide contains over 350 structured questions and verified answers covering infection control, patient care, radiopharmaceutical preparation, quality control testing, radionuclide localization, thyroid imaging, and therapeutic nuclear medicine procedures. The material begins with foundational concepts including pathogens (bacteria, fungi, parasites, viruses), universal precautions, bloodborne pathogens (HIV, HBV, HCV), sharps safety, venipuncture techniques, routes of administration (intravenous, intrathecal, intradermal), and age-specific patient care considerations from infants to geriatric patients (pages 1–6). Comprehensive radiopharmacy content includes Tc-99m kit preparation, oxidation states of pertechnetate (TcO4-), reducing agents such as stannous chloride, prevention of oxidation, and the four categories of technetium radiopharmaceuticals (oxidized soluble, oxidized particulate, reduced soluble, reduced particulate). Detailed quality control procedures are outlined, including radiochemical purity testing via thin-layer chromatography (TLC), acceptable limits for free pertechnetate (10%) and hydrolyzed-reduced technetium (≤2%), radionuclidic purity (molybdenum breakthrough testing), chemical purity (alumina breakthrough ≤10 µg Al/mL), sterility testing, apyrogenicity (LAL test), particle sizing (Tc-99m MAA 200,000–700,000 particles), and USP 797/825 sterile compounding requirements including immediate-use exemptions (within 1 hour). Localization mechanisms are reviewed in depth, including simple diffusion, active transport (I-131 NaI), capillary blockade (Tc-99m MAA), phagocytosis (Tc-99m sulfur colloid), compartmental localization (In-111 DTPA cisternogram), chemisorption (Tc-99m MDP to bone), antigen-antibody binding, and receptor binding. Organ-specific biodistribution patterns for common agents (Tc-99m MDP bone, Tc-99m MAG3 kidneys, Tc-99m tetrofosmin heart, I-123 sodium iodide thyroid, Xe-133 lungs, Tc-99m HMPAO brain) are thoroughly summarized. Advanced thyroid imaging and therapy sections cover thyroid physiology (T3, T4, TSH from anterior pituitary), hyperthyroidism, hypothyroidism, Graves disease, thyroid uptake protocols, I-123 vs I-131 comparisons, therapy dosing ranges (e.g., nodular hyperthyroidism 15–29 mCi), written directive requirements, NRC release criteria, and radiation safety precautions. Radionuclide therapies include I-131 sodium iodide, Sr-89 for bone pain palliation, Y-90 microspheres for liver tumors, Ra-223 dichloride for metastatic prostate cancer, Lu-177 dotatate for neuroendocrine tumors, and Lu-177 PSMA for prostate cancer, including indications, radiation type (alpha, beta, gamma), contraindications, monitoring labs, and patient release regulations. This document may concern: – Nuclear Medicine Technology (NMT) students – NUCM 215 students preparing for a comprehensive final exam – ARRT Nuclear Medicine certification candidates – NMTCB board preparation students – Radiopharmacy and radionuclide therapy trainees – Clinical nuclear medicine technologists reviewing regulatory and QC standards Keywords: NUCM 215 final 2026 radiopharmaceutical preparation Tc 99m stannous chloride reducing agent pertechnetate TcO4 charge radiochemical purity TLC molybdenum breakthrough test alumina breakthrough limit USP 797 825 sterile compounding particle sizing Tc 99m MAA capillary blockade localization active transport I 131 thyroid uptake I 123 vs I 131 written directive NRC thyroid ablation therapy Sr 89 bone pain palliation Y 90 microspheres liver tumors Ra 223 dichloride alpha emitter Lu 177 dotatate neuroendocrine tumors Lu 177 PSMA prostate cancer NRC release criteria mrem radionuclide quality control testing